

AMENDMENT

In the Claims:

Please replace the presently pending claims with the following claims:

72. (Amended) A method for inhibiting the growth, viability and/or survivability of cancer cells that express the nucleotide sequence SEQ. ID. No.: 1 or the cDNA in ATCC deposit 207097 (20P1F12/TMPRSS2), the method comprising:

H¹ administering to the cancer cells an antibody or fragment thereof that specifically binds to a 20P1F12/TMPRSS2 protein, thereby inhibiting the growth, viability and/or survivability of said cancer cells.

73. The method of claim 72, wherein said antibody or fragment is a monoclonal antibody, or fragment thereof.

H² 74. (Amended) The method of claim 72, wherein said antibody or fragment is a recombinant protein comprising the antigen-binding region of an antibody that specifically binds to 20P1F12/TMPRSS2 protein.

75. The method of claim 72, wherein said antibody or fragment is labeled with a detectable marker.

76. The method of claim 72, wherein said antibody or fragment is conjugated with a cytotoxic agent.

77. The method of claim 72, wherein said antibody or fragment is a human antibody or fragment.

78. The method of claim 72, wherein said antibody or fragment is administered by administering a recombinant polynucleotide that encodes the antibody or fragment thereof.

79. The method of claim 72 wherein the cancer cells are in a mammal.

80. The method of claim 79, wherein the mammal is a human and the said antibody or fragment is a recombinant protein which comprises a chimeric or humanized antibody.

81. The method of claim 80, wherein said antibody or fragment is administered with a pharmaceutically acceptable carrier.

82. The method of claim 80, said antibody or fragment is administered as the composition in a human patient dose.

Please cancel claims ~~83-84~~.